Bridgeway Capital Management’s Oragenics OGEN Stock Holding History

Bridgeway Capital Management’s Portfolio OGEN Stock Details OGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-78	Closed	-$14.7K	–	1418
2022 Q4	$14.7K	Hold	78	–	–	﹤0.01%	1352
2022 Q3	$32K	Hold	78	–	–	﹤0.01%	1370
2022 Q2	$49K	Hold	78	–	–	﹤0.01%	1282
2022 Q1	$48K	Hold	78	–	–	﹤0.01%	1291
2021 Q4	$62K	Hold	78	–	–	﹤0.01%	1237
2021 Q3	$89K	Hold	78	–	–	﹤0.01%	1257
2021 Q2	$99K	Sell	78 -171	-69%	-$225K	﹤0.01%	1313
2021 Q1	$407K	Buy	249 +171	+219%	+$311K	0.01%	1151
2020 Q4	$63K	Hold	78	–	–	﹤0.01%	1286
2020 Q3	$81K	Hold	78	–	–	﹤0.01%	1272
2020 Q2	$97K	Buy	+78	New	+$76.8K	﹤0.01%	1234
2017 Q4	–	Sell	-3	Closed	-$19K	–	1433
2017 Q3	$19K	Hold	3	–	–	﹤0.01%	1384
2017 Q2	$18K	Sell	3 -5	-63%	-$37.1K	﹤0.01%	1403
2017 Q1	$62K	Hold	8	–	–	﹤0.01%	1357
2016 Q4	$78K	Sell	8 -3	-27%	-$27.8K	﹤0.01%	1367
2016 Q3	$89K	Hold	11	–	–	﹤0.01%	1383
2016 Q2	$98K	Buy	11 +7	+175%	+$93.7K	﹤0.01%	1383
2016 Q1	$59K	Hold	4	–	–	﹤0.01%	1395
2015 Q4	$96K	Buy	+4	New	+$99.9K	﹤0.01%	1374

Other funds holding OGEN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return

WWM

Wolff Wiese Magana Carslbad, California $217M AUM 47.64% 1-Year Est. Return

Bridgeway Capital Management's OGEN Position: Q1 2023 in Review

Bridgeway Capital Management sold out of Oragenics (OGEN) in Q1 2023, closing a stake of 78 shares — an estimated $14.7K sold.

Bridgeway Capital Management first reported a position in OGEN in Q4 2015 and held it in 19 quarters. The position peaked at $407K in Q1 2021. 10 funds tracked by Wall St. Rank hold OGEN as of Q1 2023.

Bridgeway Capital Management reported no remaining Oragenics position as of Q1 2023 after selling out during the quarter.
Bridgeway Capital Management sold 78 Oragenics shares in Q1 2023, an estimated $14.7K.
Bridgeway Capital Management first reported a position in Oragenics in Q4 2015 and held it in 19 quarters.
Bridgeway Capital Management's Oragenics position peaked at $407K in Q1 2021.
10 funds tracked by Wall St. Rank held Oragenics as of Q1 2023.

Based on Bridgeway Capital Management's 13F filing for Q1 2023, filed 15 May 2023.